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Preclinical and some clinical studies suggest a relationship between perturbation in magnesium (Mg2þ)
homeostasis and pathological anxiety, although the underlying mechanisms remain largely unknown.
Since there is evidence that Mg2þ modulates the hypothalamic-pituitary adrenal (HPA) axis, we tested
whether enhanced anxiety-like behaviour can be reliably elicited by dietary Mg2þ deﬁciency and
whether Mg2þ deﬁciency is associated with altered HPA axis function. Compared with controls,
Mg2þ deﬁcient mice did indeed display enhanced anxiety-related behaviour in a battery of established
anxiety tests. The enhanced anxiety-related behaviour of Mg2þ deﬁcient mice was sensitive to chronic
desipramine treatment in the hyponeophagia test and to acute diazepam treatment in the open arm
exposure test. Mg2þ deﬁciency caused an increase in the transcription of the corticotropin releasing
hormone in the paraventricular hypothalamic nucleus (PVN), and elevated ACTH plasma levels, pointing
to an enhanced set-point of the HPA axis. Chronic treatment with desipramine reversed the identiﬁed
abnormalities of the stress axis. Functional mapping of neuronal activity using c-Fos revealed hyper-
excitability in the PVN of anxious Mg2þ deﬁcient mice and its normalisation through diazepam treat-
ment. Overall, the present ﬁndings demonstrate the robustness and validity of the Mg2þ deﬁciency
model as a mouse model of enhanced anxiety, showing sensitivity to treatment with anxiolytics and
antidepressants. It is further suggested that dysregulations in the HPA axis may contribute to the hyper-
emotionality in response to dietary induced hypomagnesaemia.
This article is part of a Special Issue entitled ‘Anxiety and Depression’.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Anxiety disorders are currently the most common neuropsy-
chiatric disorders in the USA and Europe (Andlin-Sobocki et al.,
2005; Kessler et al., 2005) and represent one of the major health
problems in the westernworld (WHO, 2004). In the aetiology of an
anxiety disorder, the simultaneous occurrence of various intrinsic
and extrinsic factors, including those relating to genes and envi-
ronment, seems to be important. Among these, there is increasing
evidence of a role of “poor” nutrition (Popkin, 2006) in the devel-
opment of some psychiatric diseases (Coppen and Bolander-
Gouaille, 2005; Kroll, 2007), despite an apparent over-nutrition in
our industrialised and globalised societies. Altered values of diverse
micronutrients, including electrolytes, minerals and vitamins, can
be linked to symptoms in psychiatric patients (Armstrong et al.,
2007; Thys-Jacobs, 2000; Zender and Olshansky, 2009). In thistori).
Y-NC-ND license.respect, changes in magnesium (Mg2þ) homeostasis have been
shown to contribute to affective disorders although some incon-
sistencies exist between the studies (for review see Murck, 2002).
Furthermore, a causal relationship between Mg2þ and anxiety is
suggested in mice with low plasma Mg2þ levels which display
increased anxiety- and/or depression-related behaviour, irre-
spective of whether these depleted levels are natural or experi-
mentally induced (Laarakker et al., 2011; Singewald et al., 2004),
although in humans equivalent evidence is scarce (Jacka et al.,
2009; Seelig, 1994). In further support of such a causal relation-
ship, Mg2þ supplementation reduces the anxiety-related behaviour
of mice (see for example Poleszak et al., 2004). Stimulated by these
ﬁndings, it has been recently suggested that hypomagnesaemia is
a possible physiological indicator of anxiety (Laarakker et al., 2011).
In the search for neurobiological mechanisms underlying
abnormal anxiety, it may be that Mg2þ is an interesting player as
it is one of the essential ions in the brain affecting many intra-
cellular and interneuronal processes. For example, Mg2þ has been
shown to modulate both glutamatergic neurotransmission (via
a voltage-dependent block of NMDA receptors) (Haddad, 2005)
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transduction pathways, including that of proteinkinase C (for
review see Murck, 2002).
In addition, Mg2þ has been shown to control the activity of the
hypothalamic-pituitary adrenocortical (HPA) axis (Murck and
Steiger, 1998), which is considered to be the main stress response
system (for review see e.g. Young et al., 2008). In the course of HPA
axis activation by the corticotropin releasing hormone (CRH),
synthesised in the paraventricular hypothalamic nucleus (PVN),
adrenal corticotropin hormone (ACTH) is released from the anterior
pituitary into the blood stream which, in turn, stimulates the
secretion of corticosterone. HPA axis activation via CRH is involved
in the generation of many different autonomic, hormonal and
behavioural changes during stress and elicits anxiety symptoms
(for review see Lowry and Moore, 2006; Young et al., 2008). It has
been suggested that dysregulations in the CRH-HPA axis system
may contribute to pathological anxiety (for review see Charney and
Drevets, 2008; Millan, 2003; Young et al., 2008).
On the basis of these data, it may be hypothesised that an
altered HPA axis function underlies the enhanced anxiety of Mg2þ
deﬁcient mice that is elicited by dietary Mg2þ restriction (when
mice are limited to 10% of their daily requirement) which results in
a 45% reduction of plasma Mg2þ levels (Singewald et al., 2004). To
address this possibility, we initially explored the robustness and
validity of the model by inducing hypomagnesaemia according to
our previous protocol for C57Bl/6J mice (Singewald et al., 2004) in
two additional mouse strains with divergent levels of inborn
anxiety (C57Bl/6N and BALB/c mice) (for review see e.g. Belzung
and Griebel, 2001; Sartori et al., 2011), and then tested the effects
of a clinically established benzodiazepine and the two antide-
pressant drugs, paroxetine and desipramine, with established
clinical efﬁcacy in patients with anxiety disorder (for review see
Plag et al., 2009) and/or with demonstrated sensitivity in Mg2þ
deﬁcient mice to reduce depression-like behaviour (Singewald
et al., 2004; Whittle et al., 2011). The emotional behaviour of
Mg2þ deﬁcient mice was assessed in a battery of anxiety tests
including the open ﬁeld test, the light/dark test, the stress-induced
hypothermia test, and the hyponeophagia test, each of which are
thought to mimic different aspects of human anxiety and which
differ in their sensitivity to detecting the anxiolytic properties of
drugs (for review see Crawley, 2000; Cryan and Holmes, 2005;
Dulawa and Hen, 2005; Vinkers et al., 2008). We then quantiﬁed
markers of HPA axis function including CRH gene expression and
plasma ACTH levels in experimentally naive or unstressed Mg2þ
deﬁcient mice. Finally, functional relevance of potentially altered
transcriptional processes in the HPA system was investigated in
Mg2þ deﬁcient mice using mapping of the immediate-early gene c-
Fos as a marker of neuronal activation in response to an anxiety-
provoking situation. Rather than addressing every aim in each
strain, we allocated speciﬁc experiments to either the C57Bl/6N or
the Balb/c strain (see Methods). Thus, using a reduced number of
animals following the principles of animal welfare, this experi-
mental design allowed revealing most information complementary
to the one gained in C57Bl/6Nmice (e.g. CRH expression in the PVN)
by adding further aspects (e.g. the inﬂuence of inborn anxiety levels
by using the Balb/c strain).2. Methods
2.1. Animals
Male C57Bl/6N and BALB/c mice were purchased from Charles River (Germany).
In all experiments adult animals (8 weeks old at the onset of the experiment) were
used. They were group-housed (up to 10 animals per cage) side-by-side in
a temperature- (22 2 C) and humidity- (50e60%) controlled animal care facility
unit under a 12 h light/dark cycle (lights on at 07:00 h), and provided with pelletedfood and water ad libitum. All experimental procedures were designed to minimise
animal suffering as well as the number of animals used and were approved by the
national ethical committee on animal care and use (Bundesministerium für
Wissenschaft und Forschung) in compliance with international laws and policies.
2.2. Diets and drug treatments
Mice assigned to Mg2þ deﬁcient groups were allowed to freely access a 0.005%
Mg2þ containing diet (Ssniff Spezialdiäten, Germany), which provided about 10%
of the daily Mg2þ requirement (Kantak, 1988) as previously described (Singewald
et al., 2004). Control mice were fed a normal, 0.2% Mg2þ containing diet (Ssniff
Spezialdiäten, Germany) which offers four times more than the minimum Mg2þ
requirement (Kantak,1988), and hereafter are always referred to as “controls”. InMg2þ
deﬁcient mice chronic treatment with either desipramine or paroxetine was given via
the drinking water. A daily drug intake of approximately 30 mg/kg desipramine
(Sigma Aldrich) and 5 mg/kg paroxetine (kindly provided by GlaxoSmithKline, UK),
respectively, was achieved by adapting the concentrations of the drugs in the drinking
solutions according to mean drinking volume and bodyweight per cage. However,
the individual dose obtainedmay have varied due to variations in the mice in terms of
water consumption and bodyweight.Micewere kept under the assigned experimental
condition (diet/drug treatment) for at least three weeks until the completion of
experiments. Diazepam (1mg/kg, dissolved in puriﬁed water; Sigma, Germany) or
vehicle were administered i.p. to mice in their home cages.
2.3. Behavioural experiments
Mice were left undisturbed in their home cages for three weeks from the start of
diet and/or chronic drug treatment until the onset of behavioural experiments. After
animals had been habituated to the testing room for at least 24 h, behavioural
experiments were carried out between 09:00 h and 14:00 h. Testing chambers were
carefully cleaned with tap water and a damp towel after each animal had been
tested. In order to decrease the number of animals used, the behavioural experi-
ments, with at least two days of rest between each, were conducted in the same
animals starting with the stress-induced hyperthermia test (Lecci et al., 1990), the
open ﬁeld test (Broadhurst, 1961; DeFries et al., 1974), the light/dark test (Crawley,
1981), and the hyponeophagia test (Bodnoff et al., 1988) according to protocols
used previously in our lab (Busquet et al., 2009; Singewald et al., 2004; Tschenett
et al., 2003; Whittle et al., 2011).
2.3.1. Stress-induced hyperthermia
Mice were housed singly for at least 24 h prior to testing. With the mouse in its
homecage, a glycerol lubricated thermistor probe connected to a digital thermom-
eter (DM 852, Ellab, Denmark) was inserted into its rectum and left there until the
temperature was stable for 20 s. The accuracy of the thermometer was 0.1 C. Rectal
temperature was measured in each mouse at T1, and then at T2 10 min later. As the
intubation of the rectal probe for assessing the core temperature has been shown to
sufﬁciently initiate a stress response in mice (Bouwknecht et al., 2007), the differ-
ence between temperatures T2 and T1 was taken as evidence of stress-induced
hyperthermia. At the end of the stress-induced hyperthermia test, animals were
group housed again for the following tests.
2.3.2. Open ﬁeld test
The open ﬁeld consisted of a plastic box (414141 cm) equipped with an
automated activity monitoring system (TruScan, Coulbourn Instruments, USA). The
area of the open ﬁeld, illuminated with 150 lux, was divided into a 28 28 cm
central zone and a surrounding border zone. Mice were placed individually into the
periphery of the open ﬁeld and allowed to explore it for 10 min. The following
anxiety-related parameters were recorded: entries into the central zone, time spent
in it, number of rearings, and the overall distance travelled.
2.3.3. Light/dark test
The light/dark testing arena (414141 cm; TruScan, Coulbourn Instruments,
USA) was divided into two halves, comprising a white, aversive compartment illu-
minated with 400 lux at ﬂoor level and a dark, safe compartment covered by a black
top illuminated with 10 lux. The compartments were connected by a small opening
(7 7 cm) located in the centre of the partition at ﬂoor level. Animals were indi-
vidually placed into the dark compartment facing away from the opening and
allowed to freely explore the apparatus for 10 min. During the 10 min testing period
the behaviour displayed by each mouse was automatically registered and the
following anxiety-related parameters quantiﬁed: the latency to the ﬁrst entry into
the lit compartment, number of entries into the lit compartment, time spent in the
lit compartment, number of rearings and overall distance travelled by the mice.
2.3.4. Hyponeophagia test
This paradigm was carried out in the open ﬁeld arena (see above) with lighting
set at 40 lux. Mice were food deprived, but allowed to freely drink water overnight.
Animals were placed into a corner of the arena and the latency they took to start
consuming oatﬂakes placed in the centre of the testing arenawas registered, as well
as the distance travelled.
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In a separate cohort of the C57Bl/6N strain, mice were fed either the control
diet, the Mg2þ restricted diet, or the Mg2þ restricted diet and concomitant
chronic desipramine treatment as described above and were left undisturbed in
their home cages for three weeks. These experimentally naive mice were then
sacriﬁced by carbon dioxide inhalation in a saturated chamber in accordance
with established welfare guidelines (Hackbarth et al., 2000) and their brains
were quickly removed. Consecutive, frozen sections (12 mm) at the level of the
PVN, central amygdala and Barrington’s nucleus were prepared on slides
(Paxinos and Franklin, 2001) and further processed for in situ hybridisation as
previously described (Keck et al., 2005; Sartori et al., 2004). Brieﬂy, a speciﬁc,
[35S]-labelled oligonucleotide probe (Microsynth, Balgach, Switzerland) directed
against bases 64e111 of the rat prepro-CRH clone (Jingami et al., 1985) showing
high homology with the murine gene (accession number NM_205769.1) was
hybridised to brain sections at 35 C overnight. Subsequently, slides were
washed in 0.5 saline sodium citrate three times at 55 C followed by two washes
at room temperature. Dry slides were exposed to BioMax MR ﬁlm (Kodak, USA)
for 7‑14 days. Quantitative analysis was performed on digitised autoradiograms
using image analysis software (AnalySIS, Soft Imaging Systems, Germany). In
two sections per animal, mean grey values from regions of interest were
determined and converted into optical densities, and then further into nCi/g
tissue equivalent using autoradiographic [14C]-microscales (Amersham Biosci-
ences, UK) corrected for [35S].2.5. Radioimmunoassays
At least ﬁve days after the last behavioural experiment, C57Bl/6N mice assigned
to the control diet, the Mg2þ deﬁcient diet, or the Mg2þ deﬁcient diet and
concomitant chronic treatment with desipramine were euthanised using carbon
dioxide in a saturated chamber (Hackbarth et al., 2000). Trunc blood was collected
from the sacriﬁced animals in EDTA-coated vials (Greiner Bio-one GmbH, Austria)
and centrifuged (3000 rpm) for 10 min at 4 C. Plasma samples were stored
at 20 C until measurement took place. Plasma ACTH and corticosterone concen-
trations were determined using commercially available kits (MP Biomedicals, USA),
with an intra- and inter-assay variability of less than 10% and a lower detection limit
of 6 pg/mL and 8 ng/mL, respectively.Table 1
Effect of Mg2þ deﬁciency and chronic paroxetine treatment on behavioural
measures assessed in diverse tests of anxiety in C57Bl/6N mice.
Control MgD MgDþ PAR
Stress-induced hyperthermia
T1 (C) 35.8 0.2 36.5 0.1* 35.6 0.2##
T2 (C) 36.9 0.1 37.2 0.1 36.7 0.2
T2 T1 (C) 1.1 0.1 0.7 0.1* 1.2 0.1#2.6. c-Fos expression in response to emotional challenge
30 min after i.p. injection of either diazepam (1 mg/kg) or vehicle, BALB/c mice
were subjected to the open arm exposure test as previously described (Muigg et al.,
2009). During the 10-min testing period inwhich the animals were allowed to freely
explore the open arm of an elevated plus maze, entries into and time spent in the
proximal and distal compartments of the open arm as well as the total distance
travelled were automatically quantiﬁed by the Videomot tracking system (TSE
Systems, Germany). Two hours later mice were deeply anaesthetised (200 mg/kg
sodium pentobarbital, i.p.) and transcardially perfused with saline followed by
paraformaldehyde solution (4% in 0.1 M phosphate buffered saline, pH 7.4), and their
brains were removed. Coronal brain sections (100 mm) at the level of the PVN were
processed for c-Fos immunocytochemistry using a polyclonal rabbit anti-c-Fos
primary antibody (1:20,000; Santa Cruz Biotechnology, USA), a biotinylated goat
anti-rabbit secondary antibody (1:200; Vector Laboratories, USA) and an avidin-
biotin-horseradish peroxidase procedure (Vectastain ABC kit, Vector laboratories,
USA) with 3,30-diaminobenzidine (Sigma, Germany) as chromogen according to
previous protocols (Muigg et al., 2009; Singewald et al., 2003). The PVN cells con-
taining a nuclear brown-black reaction product were considered to be c-Fos-positive
cells and their number was counted bilaterally in a representative tissue area of
0.01 mm2 with the help of a light microscope (Olympus BX-40) equipped with an
ocular grid.Open ﬁeld test
Centre entries (n) 31.8 3.0 23.3 3.2a 17.6 3.3**
Centre time (s) 87.8 12 51.2 8.4* 45.7 8.9**
Rearings (n) 25.7 3.2 18.4 2.7a 12.3 2.0**
Distance travelled (cm) 2399 133 2060 132 1892 168
Light/dark test
Latency (s) 85.9 14 229 44** 224 25**
Entries into the lit arena (n) 10.9 1.0 8.8 1.4 6.4 1.2*
Time spent in lit arena (s) 161 22 155 27 73.7 15**#
Rearings (n) 17.9 1.9 17.9 2.3 9.2 1.2**##
Distance travelled (cm) 2539 120 2215 127 2199 87
Data are presented as means SEM. n¼ 10 for control and MgD groups, and n¼ 10
or 5 (in the stress-induced hyperthermia test) for MgDþ PAR group.
a P< 0.08, *P< 0.05, **P< 0.01 for MgD vs. control mice; #P< 0.05, ##P< 0.01
MgDþ PAR vs. MgD mice. MgD: Mg2þ deﬁcient mice; MgDþ PAR: Mg2þ deﬁcient
mice chronically treated with paroxetine.2.7. Data presentation and statistics
Data represent mean standard error of the mean (SEM). Exact n-numbers are
given in table and ﬁgure legends. Variations in n-numbers between tests and/or
assays are explained by the combination of at least two separate sets of experiments
using different n-numbers and the early withdrawal of some animals for other
experiments, in part reported elsewhere (e.g. Whittle et al., 2011). Statistical analysis
was performed using STATISTICA 7.1 (Stat Soft, Inc., USA). First, all experimental
groups were tested for statistically signiﬁcant outliers using the Grubb’s test. Data
were then tested for homogeneity of variances using Levene’s test. If a parametric
distributionwas revealed, the datawere further analysed using either a one- or two-
way ANOVA followed by Fisher’s LSD test when allowed. Non-parametric data
were statistically analysed using a KruskaleWallis ANOVA test followed by
ManneWhitney U tests. Statistical signiﬁcance was set at P< 0.05 while non-
signiﬁcant P values were reported as n.s.3. Results
At the beginning of the experiments, C57Bl/6N mice assigned to
control diet, Mg2þ deﬁcient diet or Mg2þ deﬁcient diet chronically
treated with either desipramine or paroxetine did not differ in
bodyweight (mean bodyweight of 22.5 0.1 g). After three weeks
under the experimental conditions (diet/drug), bodyweight gain
differed between experimental groups (F1,22¼ 31.520, P< 0.001).
Within this time period Mg2þ deﬁcient animals (þ5.11.1%) put on
more bodyweight than control animals (þ2.4 0.8%; P< 0.05).
Compared with the Mg2þ deﬁcient group, the gain in bodyweight
was increased in Mg2þ deﬁcient mice chronically treated with
paroxetine (þ10.91.0%; P< 0.001) while the Mg2þ deﬁcient mice
chronically treated with desipramine even lost weight (2.91.1%;
P< 0.001). Similar to C57Bl/6N mice, bodyweights did not differ
between controlmice andMg2þ deﬁcientmice (meanbodyweight of
20.0 0.1 g) of the Balb/c strain at the beginning of the experiments.
Three weeks of feeding a Mg2þ restricted diet caused a reduced
increase in bodyweight in Balb/c mice (control: þ11.8 1.3%: Mg2þ
deﬁcient: þ5.8 1.5 g; P< 0.01).
3.1. Effect of Mg2þ deﬁciency and chronic antidepressant treatment
on anxiety-related behaviour in C57Bl/6N mice
Using the stress-induced hyperthermia paradigm (for review
see Vinkers et al., 2008), anxiety-related behaviour of C57Bl/6N
mice assigned to either the control diet, the Mg2þ deﬁcient, or the
Mg2þ deﬁcient diet and parallel chronic paroxetine treatment was
tested (Table 1). Basal body temperature of control mice was low
reaching 35.8 0.2 C, which indicates that animals were not pre-
stressed under the given experimental conditions. There was
a signiﬁcant difference between mice in the body temperature T1
under unstressed conditions (F1,22¼ 6.400, P< 0.01). Subsequent
post-hoc analysis designated increased basal body temperature
in Mg2þ deﬁcient animals compared with controls and paroxetine-
treated Mg2þ deﬁcient mice. The mild stress of measuring T1
caused a rise in body temperature (T2) which by this stage no
longer differed between the three experimental groups. The stress-
induced rise in body temperature was smaller in Mg2þ deﬁcient
mice than it was in either control or paroxetine-treated Mg2þ
deﬁcient mice (F1,21¼4.132, P< 0.05).
Fig. 1. Effect of Mg2þ deﬁciency and chronic paroxetine treatment on selected anxiety-related measures in C57Bl/6N mice. A. In mice fed a Mg2þ restricted diet (MgD) the time
spent in the anxiogenic centre of an open ﬁeld was decreased compared with mice fed the control diet (control) indicating enhanced anxiety-related behaviour. B. Anxiety-related
behaviour was also elevated in the light/dark test as indicated by the increased latency to enter the (anxiogenic) brightly lit compartment. Chronic treatment with paroxetine
(MgDþ PAR) did not alter anxiety-related behaviour of Mg2þ deﬁcient mice in these tests. n¼ 10 per experimental group. Data represent means SEM. *P< 0.05, **P< 0.01 for
Mg2þ deﬁcient vs. control mice.
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ﬁeld test and light/dark test which are based on an exploration-
avoidance conﬂict (for review see e.g. Cryan and Holmes, 2005).
In the open ﬁeld test (Table 1), experimental groups differed
signiﬁcantly in terms of number of entries into the centre of
the testing arena (F2,27¼ 5.021, P< 0.05), time spent there
(F2,26¼ 5.284, P< 0.05; Fig. 1) as well as number of rearings
(F2,27¼6.381, P< 0.01). Speciﬁcally, compared with mice fed the
control diet, these measures were lower in Mg2þ deﬁcient and
paroxetine-treated Mg2þ deﬁcient animals. In the light/dark test
(Table 1; Fig. 1), we observed a signiﬁcant difference in the latency
to enter the brightly lit, aversive compartment of the light/dark
chamber (F2,27¼ 7.122, P< 0.01) as this latency was increased in
both groups fed a Mg2þ restricted diet (Fig. 1). Furthermore, there
was a signiﬁcant group effect in terms of the number of entries into
(F2,27¼3.430, P< 0.05) and time spent (F2,27¼ 5.045, P< 0.05) in
the lit compartment of the light/dark test chamber, and in the
rearing numbers (F2,27¼ 7.361, P< 0.01). Paroxetine-treated Mg2þ
deﬁcient mice displayed reduced values in all three parameters
compared with both control and Mg2þ deﬁcient groups (Table 1).
Next, we subjected all C57Bl/6N mice to the hyponeophagia para-
digm,oneof the fewtestswhicharesensitive totheanxiolyticeffectsofFig. 2. In the hyponeophagia test, the latency to eat a preferred food placed in the centre of
control diet (control; n¼ 19), the Mg2þ deﬁcient diet (MgD; n¼ 16), or the Mg2þ deﬁcient di
paroxetine (MgDþ PAR; n¼ 16). Data represent means SEM. *P< 0.05, **P< 0.01, ***P< 0
mice vs. Mg2þ deﬁcient mice.chronic antidepressant treatment (Bodnoff et al., 1989; Dulawa and
Hen, 2005; Gordon and Hen, 2004). There was a signiﬁcant group
effect in the latency to eat (F3,58¼ 11.828, P< 0.001) the preferred food
placed into the centre of the testing arena (Fig. 2). Mg2þ deﬁciency
caused an increase in the latency to eat. InMg2þ deﬁcientmice chronic
desipramine treatment reduced the latency to eat compared with
untreated mice while long-term treatment with paroxetine did not
affect this behavioural parameter (Fig. 2). Mg2þ deﬁciency and long-
term antidepressant treatments did not alter general locomotor
activity as indicated by the distances travelled in the open ﬁeld test
(n.s.; Table 1), the light/dark test (n.s.; Table 1), and the hyponeophagia
test (n.s.; Fig. 2). All together theseﬁndings suggest that chronicMg2þ
deﬁciency was anxiogenic and that chronic desipramine, but not
paroxetine treatment was effective in reducing anxiety in this model.
3.2. Effect of Mg2þ deﬁciency and desipramine treatment on
prepro-CRH mRNA expression in the brain of C57Bl/6N mice
In C57Bl/6N mice prepro-CRH mRNA expression, as visualised
by in situ hybridisation, was high in the PVN and moderate in the
central amygdala and Barrington’s nucleus (Table 2), which is in
good accordance with previous studies (e.g. Keegan et al., 1994). Inthe testing arena and the distance travelled is shown for C57Bl/6N mice fed either the
et and additional long-term treatment with either desipramine (MgDþDMI; n¼ 12) or
.001 for Mg2þ deﬁcient vs. control mice, ###P< 0.001 for drug-treated Mg2þ deﬁcient
Table 2
Effect of Mg2þ deﬁciency and chronic desipramine treatment on prepro-CRH mRNA




325 18 450 28*** 313 16###
Central amygdala 140 9.0 150 13 145 9.0
Barrington’s nucleus 164 9.0 168 16 162 7.0
Data expressed in nCi/g T.E. are presented as means SEM. n¼ 10 per experimental
group for the paraventricular hypothalamic nucleus and central amygdala, n¼ 9 per
experimental group for the Barrington’s nucleus. ***P< 0.001 for MgD vs. control
mice, ###P< 0.001 MgDþDMI vs. MgD mice. MgD: Mg2þ deﬁcient mice;
MgDþDMI: Mg2þ deﬁcient mice chronically treated with desipramine.
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P< 0.001) as the abundance of prepro-CRHmRNAwas increased in
Mg2þ deﬁcient mice compared with mice fed the control diet
(P< 0.001), and chronic treatment with desipramine normalised
this effect in Mg2þ deﬁcient mice (P< 0.001) (Table 2, Fig. 3). In
contrast to the PVN, prepro-CRH mRNA expression did not differ
between experimental groups in the central amygdala (n.s.) or in
the Barrington’s nucleus (n.s.) (Table 2).3.3. Effect of Mg2þ deﬁciency and desipramine treatment on plasma
ACTH and corticosterone levels in C57Bl/6N mice
Under unstressed conditions plasma ACTH levels (H2,46¼ 7.466,
P< 0.05), but not corticosterone levels (n.s.), differed between
experimental groups of the C57Bl/6N strain (Table 3). Mg2þ deﬁ-
cient animals showed increased plasma ACTH levels compared
with controls fed a normal Mg2þ containing diet (P< 0.01). Chronic
treatment with desipramine decreased the elevated ACTH plasma
levels of Mg2þ deﬁcient mice, which no longer differed in this
respect from control mice (n.s.).3.4. Effect of Mg2þ deﬁciency and diazepam on anxiety-related
behaviour and c-Fos expression in response to open
arm exposure in Balb/c mice
In an attempt to gain additional evidence for a possible func-
tional relevance of increased PVN prepro-CRH mRNA expression in
the Mg2þ deﬁciency-induced enhanced anxiety-related behaviour,
c-Fos expressionwas used to map neuronal activation in the PVN in
response to the mild emotional challenge of open arm exposure. AsFig. 3. This ﬁgure shows (A) representative autoradiograms and (B) quantiﬁcation of prepro
fed either the control diet (control; n¼ 10), the Mg2þ deﬁcient diet (MgD; n¼ 10), or the M
also provides quantiﬁcation of unspeciﬁc hybridisation. Data represent mean SEM. *P< 0
treated Mg2þ deﬁcient mice vs. Mg2þ deﬁcient mice.with the C57Bl/6N strain, Mg2þ deﬁciency increased anxiety-
related behaviour in BALB/c mice which was reversed by diaz-
epam treatment as indicated by signiﬁcant dietary and drug effects
in the measures “percentage of entries into the anxiogenic distal
part of the open arm” (diet: F1,35¼12.615, P< 0.01; drug:
F1,35¼15.359, P< 0.001, Table 4, Fig. 4A) and “total distance trav-
elled” (diet: F1,35¼ 6.120, P< 0.05; drug: F1,36¼ 33.519, P< 0.001;
Table 4). Furthermore, diazepam signiﬁcantly affected the
percentage of time spent in the distal compartment (F1,35¼10.352,
P< 0.01) (Table 4).
Exposure to the open arm of an elevated plus maze induced
c-Fos expression in the PVN (Fig. 4B and C). Two-way ANOVA
revealed a signiﬁcant diet drug interaction in terms of the
number of c-Fos-positive cells in the magnocellular portion of the
PVN (F1,36¼ 20.8301, P< 0.001) while there was a dietary effect in
its parvocellular portion (F1,36¼ 4.187, P< 0.05; data not shown).
Speciﬁcally, Mg2þ deﬁciency increased emotional challenge-
induced c-Fos expression and diazepam normalised it in BALB/c
mice (Fig. 4B and C).
4. Discussion
In the present study we have shown that dietary Mg2þ restric-
tion reproducibly enhanced anxiety-related behaviour in mice and
that this effect was robust in terms of different strains and para-
digms used. Mg2þ deﬁciency was associated with an increased
transcription of prepro-CRH in the PVN, the main output region of
the HPA axis, and elevated plasma ACTH levels pointed to an up-
regulated stress system. Indeed, in Mg2þ deﬁcient mice expres-
sion of the immediate-early gene c-Fos was increased in the PVN in
response to a mildly anxiety-provoking situation indicating func-
tional over-reactivity of this brain area. In parallel with a reversal of
the behavioural changes brought about by Mg2þ deﬁciency, the
observed abnormalities in the HPA axis system were restored by
anxiolytic and antidepressant drug treatments. These data support
a relationship between low Mg2þ levels and both anxiety-related
behaviour and a modulated stress axis.
4.1. Effect of Mg2þ deﬁciency and chronic antidepressant
treatment on mice
In the present study chronic feeding of C57Bl/6N mice with
a lowMg2þ containing diet enhanced anxiety-like behaviour in the-CRH mRNA expression in the paraventricular hypothalamic nucleus for C57Bl/6N mice
g2þ deﬁcient diet after long-term treatment with desipramine (MgDþDMI; n¼ 10); it
.05, ***P< 0.001 for Mg2þ deﬁcient vs. control mice and ###P< 0.001 for desipramine-
Table 3
Effect of Mg2þ deﬁciency and chronic desipramine treatment on basal ACTH and
corticosterone plasma levels in C57Bl/6N mice.
Control MgD MgDþDMI
ACTH (pg/ml) 89.7 14.7 (19) 199 30.4 (19)** 136 46.0 (8)
Corticosterone (ng/ml) 74.9 13.3 (30) 105 18.1 (30) 83.8 15.6 (21)
Data represent means SEM. n e numbers per experimental group are given in
parentheses behind values. **P< 0.01 forMgD vs. control mice. MgD:Mg2þ deﬁcient
mice; MgDþDMI: Mg2þ deﬁcient mice chronically treated with desipramine.
S.B. Sartori et al. / Neuropharmacology 62 (2012) 304e312 309open ﬁeld and light/dark test compared with controls. These ﬁnd-
ings are in line with our previous results using the C57Bl/6J sub-
strain (Singewald et al., 2004) which were independently
conﬁrmed by Muroyama et al. (2009). In addition, we included
another anxiety test, the hyponeophagia test, which refers to the
inhibition of feeding in rodents upon exposure to novelty and
which is one of the limited number of tests available in terms of its
sensitivity to the anxiolytic effects of chronic, but not acute anti-
depressant treatment (for review see Dulawa and Hen, 2005). In
this test the measures of anxiety-related behaviour were also
enhanced in Mg2þ deﬁcient mice compared with mice fed the
control diet. In contrast to our previous study (Singewald et al.,
2004), bodyweight gain was enhanced in Mg2þ deﬁcient
compared with control mice excluding the argument that reduced
appetite may have contributed to the enhanced latency to feed.
This, however, seems unlikely since the enhanced latency to feed
was fully reversed by desipramine which is reported to exert
anorexic effects or no change in bodyweight gain, rather than
orexigenic effects at the beginning of treatments (Gobshtis et al.,
2007; Sartori et al., 2004; Yalcin et al., 2005).
In the open ﬁeld test, light/dark test and hyponeophagia test
therewas a trend towards a reduced anxiety-induced locomotion in
Mg2þ deﬁcient mice compared to mice fed the control diet.
However, it is unlikely that the enhanced anxiety-related behaviour
induced by Mg2þ deﬁciency is inﬂuenced by unspeciﬁc effects on
locomotion or due to a general motor impairment asMg2þ deﬁcient
and control groups do not differ in locomotor activity in their home
cages as well as in the rotarod test (Singewald et al., 2004). Never-
theless, we examined the anxiogenic effects of Mg2þ deﬁciency in
a test that is entirely independent of locomotion, the stress-induced
hyperthermia test. We found that even under unstressed condi-
tions, body temperature was increased in Mg2þ deﬁcient mice
compared with control mice which seemed to limit their hyper-
thermic response to exposure to themild stress. The increased basal
body temperature may therefore point towards a kind of
chronically-stressed state induced by Mg2þ deﬁciency which
caused a new set-point for body temperature (Keeney et al., 2001).
Indeed, elevated basal body temperature is reported in chronically-
stressed animals (Hayashida et al., 2010; Keeney et al., 2001) as well
as in mutant mice (Guilloux et al., 2011) displaying signs of
enhanced anxiety- and/or depression-related behaviour. In furtherTable 4
Effect of Mg2þ deﬁciency and diazepam (1 mg/kg) on anxiety-related behaviour of
BALB/c mice in response to open arm exposure.
Control Mg2þ deﬁciency
Vehicle diazepam Vehicle diazepam
Time in distal
compartment (%)
11.3 2.7 15.7 1.3 2.2 0.8* 15.7 4.6##
Distance
travelled (cm)
306 25 676 88### 162 39 512 70###
Data are presented as means SEM. n¼ 10 per experimental group with the
exception of vehicle-treated control group where n¼ 9. *P< 0.05 for Mg2þ deﬁcient
vs. control mice, ##P< 0.01, ###P< 0.001 for diazepam vs. vehicle treatment.support of this idea, the HPA-stress axis seems to be up-regulated in
Mg2þ deﬁcient compared with control mice (see below).
During the open arm exposure test Mg2þ deﬁciency also
increased anxiety-related behaviour in BALB/c mice, a mouse strain
with emotionality reported to be different to or even opposite that
of C57Bl/6 mice (Griebel et al., 2000). This effect coincided with an
attenuated distance travelled which is thought to be a sign of
increased neophobia reﬂecting “trait” anxiety, observed particu-
larly in BALB/c mice (for review see Belzung and Griebel, 2001).
Thus, it seems that dietary Mg2þ deﬁciency further increased the
innate anxiety of this strain. In addition to experimentally reducing
plasma Mg2þ levels, natural low Mg2þ levels across mouse strains
have also been associated with enhanced anxiety-like behaviour.
For example, A/J mice characterised by enhanced anxiety-related
behaviour compared with C57Bl/6 mice have lower plasma Mg2þ
levels (Laarakker et al., 2011).
We next tested whether it was possible to attenuate the
increased anxiety-related behaviour of Mg2þ deﬁcient mice by the
application of clinically effective pharmacotherapies. Application of
the experimentally and clinically established anxiolytic diazepam
(Aerni et al., 2004; Bentz et al., 2010; Soravia et al., 2006; for review
see Millan, 2003) reversed the enhanced anxiety-related behaviour
of Mg2þ deﬁcient BALB/c mice, while it was ineffective in control
mice suggesting efﬁcacy of diazepam particularly in subjects with
high emotionality. Likewise, speciﬁcity of action of diazepam is
described in the HAB mouse model (Kromer et al., 2005) and
various psychopathological rat models of enhanced anxiety
including the HAB rats (Liebsch et al., 1998). In addition to the
classical anxiolytic drug diazepam, chronic desipramine treatment
also reduced anxiety-related behaviour of Mg2þ deﬁcient C57BL/6N
mice in the hyponeophagia test (the present study), while it was
not effective in altering anxiety-like behaviour in the open ﬁeld test
and light/dark test (Singewald et al., 2004) whose limited sensi-
tivity to the anxiolytic effects of chronic antidepressant treatments
is well known (for review see Belzung, 2001). Anxiolytic effects of
chronic desipramine treatment have also been reported in zinc-
deﬁcient mice displaying signs of enhanced anxiety-related
behaviour (Whittle et al., 2009) as well as in rodents with normal
levels of anxiety (Bodnoff et al., 1989, 1988; Merali et al., 2003;
Santarelli et al., 2003). Hyponeophagia-based models in mice and
rats predict the anxiolytic effects of antidepressants in a manner
that is consistent with the time-course of their effects in humans
(for review see Dulawa and Hen, 2005). In the clinical setting
imipramine, the prodrug of desipramine, is used in the treatment of
anxiety disorders that include generalised anxiety disorder, panic
disorder and post-traumatic stress disorder (for review see Plag
et al., 2009). The ﬁndings of anxiolytic effects resulting from diaz-
epam and chronic desipramine treatment in Mg2þ deﬁcient mice
further underlines the validity of the Mg2þ deﬁciency model of
enhanced anxiety-related behaviour in mice.
In contrast to desipramine, chronic treatment with paroxetine
did not affect anxiety-related behaviour in the hyponeophagia test.
This ﬁnding is not due to possible underdosing as a dose of 5 mg/kg
paroxetine has been recently shown to be effective in reducing
depression-like behaviour in Mg2þ deﬁcient mice (Whittle et al.,
2011). Although, to our knowledge, paroxetine has not so far been
tested in the hyponeophagia test, another SSRI, ﬂuoxetine, has
proven to exert anxiolysis following chronic, but not acute, appli-
cation in rodents (Bodnoff et al., 1989; Dulawa et al., 2004;
Santarelli et al., 2003), suggesting that Mg2þ deﬁcient mice are
insensitive to the anxiolytic effects of chronic SSRI (paroxetine)
treatment. This ﬁnding is of potential research interest, as Mg2þ
deﬁcient mice may model a considerable proportion of patients
with an anxiety disorder that does not respond to SSRI treatment
(Liebowitz, 1997; for review see Zamorski and Albucher, 2002).
Fig. 4. Effect of Mg2þ deﬁciency and diazepam treatment (1 mg/kg, i.p.) on behaviour and c-Fos expression in the paraventricular hypothalamic nucleus (PVN) of BALB/c mice
following exposure to the open arm of an elevated plus maze. A. In mice fed a Mg2þ restricted diet the anxiety-related behaviour was elevated as indicated by the number of entries
into the (anxiogenic) distal compartment of the open arm. Treatment with diazepam normalised this anxious phenotype. B. Compared with vehicle-treated controls, c-Fos induction
was increased in the magnocellular portion of the PVN in Mg2þ deﬁcient mice and was reversed by diazepam treatment. C. Representative photograph (scale bar¼ 100 mm) showing
delineation of the PVN regions analysed with the help of a mouse brain atlas (Paxinos and Franklin, 2001). D. High magniﬁcation photograph showing c-Fos-positive cells in the
magnocellular portion of the PVN in all experimental groups. Data represent mean SEM. n¼ 10 per experimental group. *P< 0.05, ***P< 0.001 for Mg2þ deﬁcient vs. control mice,
###P< 0.001 for diazepam vs. vehicle. 3V: third ventricle; DZP: diazepam; magno: magnocellular portion of the PVN; parvo: parvocellular portion of the PVN; V: vehicle.
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which is modulated by therapeutic drug treatment
In an attempt to gain insight into neurobiological mechanism(s)
underlying the enhanced anxiety-related behaviour of Mg2þ deﬁ-
cient mice, we followed a hypothesis-driven approach rather than
using an unbiased technique (see also German-Fattal et al., 2008)
that was previously used in our lab, where brain protein changes
were identiﬁed that were correlated with the altered depression-
related behaviour of Mg2þ deﬁcient mice (Whittle et al., 2011).
Mg2þ modulates various neurobiological mechanisms, including
neurotransmitter systems and the HPA axis (for review see Murck,
2002). The HPA axis is an interesting substrate as it is known to
play a role in stress processing and in normal and pathological
anxiety (for review see Charney and Drevets, 2008; Millan, 2003;
Young et al., 2008). Speciﬁcally, as Mg2þ reduces HPA axis activity
(Held et al., 2002; Murck and Steiger, 1998), a disinhibition of this
system during Mg2þ deﬁciency may be postulated. In order to
address this hypothesis, we investigated markers of HPA axis
activity, including prepro-CRH transcription and ACTH plasma
levels, in experimentally naive or unstressed control mice, Mg2þ
deﬁcient mice and Mg2þ deﬁcient mice chronically treated with
desipramine, the drug that was shown to be behaviourally active.
The abundance of prepro-CRH mRNAwas enhanced in the PVN,
the main output region of the HPA axis, of Mg2þ deﬁcient mice
compared with control mice. In addition, ACTH plasma levels were
elevated in Mg2þ deﬁcient mice, indicating that the increase in
prepro-CRH transcription translated into increased ACTH release
from the pituitary, while corticosterone plasma levels did not differ
between experimental groups. A similar divergence betweenbaseline plasmaACTH and corticosterone levels has beenpreviously
reported in low aggressive mice and may be explained by altered
adrenocortical sensitivity to ACTH (Veenema et al., 2003). In Mg2þ
deﬁcient mice the ﬁndings of elevated abundance of prepro-CRH
mRNA and ACTH release point towards an up-regulated set-point
of the HPA axis during Mg2þ deﬁciency which is also observed in
some, but not all patients with an anxiety disorder (for review see
Charney and Drevets, 2008; Young et al., 2008), and this is therefore
suggested to contribute to the enhanced anxiety-related behaviour
of Mg2þ deﬁcient mice. In further support of this, we observed
increased neuronal activity in the PVN of Mg2þ deﬁcient BALB/c
mice in response to the open arm of an elevated plus maze which,
though considered as being mildly anxiogenic, is able to cause the
release of stress hormones and to induce neuronal activation in
rodents comparedwith an unstressed condition (Muigg et al., 2009;
Nguyen et al., 2009; Salome et al., 2004). Interestingly, while stress-
induced neuronal activation has been shown to be blunted in
cortical areas of Balb/c mice compared with C57Bl/6 mice, PVN
activation is similar between the two strains (O’Mahony et al., 2010)
supporting the use of Balb/c mice complementary to C57Bl/6Nmice
in the present study. The ﬁnding of an over-reactive PVN in Mg2þ
deﬁcient animals, thus, demonstrates functional relevance of the
PVN in mediating hyper-anxiety. This over-reactivity of the PVN
may be triggered by the enhanced transcription rate of prepro-CRH.
Like Mg2þ deﬁcient mice, HAB mice and rats with high trait anxiety
(Kromer et al., 2005; Liebsch et al., 1998), also show increased c-Fos
expression in the PVN compared with their low anxiety (LAB)
counterparts in response to open arm exposure (Muigg et al., 2009;
Salome et al., 2004). In the PVN, CRH levels have been shown to be
up-regulated by a number of different stressors (for review see e.g.
S.B. Sartori et al. / Neuropharmacology 62 (2012) 304e312 311Holsboer, 2000), including neonatal maternal separation,
a proposed animal model of anxiety and depression (for review see
Sartori et al., 2011), and in rats with high trait anxiety (Bosch et al.,
2006). In line with the present ﬁndings, CRH concentrations in the
cerebrospinal ﬂuid are elevated in chronic, combat-related post-
traumatic stress disorder (Baker et al., 1999; Bremner et al., 1997).
However, such reported abnormalities of the HPA axis are incon-
sistent between studies as, for example, basal plasma or urine
cortisol concentrations have been shown to be increased, unaltered
or decreased in patients with anxiety disorder (for review see
Charney and Drevets, 2008; Young et al., 2008).
In Mg2þ deﬁcient mice, application of the benzodiazepine
diazepam reduced the hyper-reactivity of the PVN in response to
a mild emotional challenge. The ability of benzodiazepines to
decrease stress-induced neuronal activation in the PVN has been
previously shown in mice (Imaki et al., 1995) and rats (Beck and
Fibiger, 1995; de Medeiros et al., 2005). Furthermore, chronic
desipramine treatment via the drinking water normalised CRH
overexpression in the PVN and elevated ACTH plasma levels.
Tricyclic antidepressants have been shown to attenuate HPA axis
activity which is thought to contribute to their anxiolytic and
antidepressant actions (for review see Holsboer, 2000). Both ﬁnd-
ings further support the idea of a critical involvement of the HPA
axis, and in particular of the PVN, in terms of contributing to the
anxiogenic effects of Mg2þ deﬁciency. However, it should be noted
that due to an existing comorbid link between anxiety and
depression, it is not possible to make a clear distinction between
mechanisms underlying anxiety alone. Indeed, Mg2þ deﬁcient mice
are also characterised by a pro-depressive phenotype which can be
reversed by chronic antidepressant treatments including desipra-
mine and paroxetine (Muroyama et al., 2009; Singewald et al.,
2004; Whittle et al., 2011). Thus, it may be that the up-regulated
HPA axis in Mg2þ deﬁcient mice also is of relevance to the
enhanced depression-like behaviour. In humans too, depression
has been shown to be associated with an abnormally elevated HPA
axis which is restored after clinical improvement (for review see
e.g. Holsboer, 2000).
Taken together, the present ﬁndings demonstrate the robust-
ness and validity of the Mg2þ deﬁciency model as model of
enhanced anxiety-related behaviour and further supports
emerging evidence in humans that reduced Mg2þ levels are asso-
ciated with different facets of anxiety behaviour (Jacka et al., 2009;
Seelig, 1994). Hence, an inverse relationship between Mg2þ and
anxiety is suggested by these data. In terms of the induced anxio-
genesis, the Mg2þ deﬁciency model appears to be reproducible
across mouse strains, regardless of the level of inborn anxiety
displayed. Finally, it is suggested that dysregulations in the HPA axis
may contribute to the hyper-emotionality induced by dietary
induced hypomagnesaemia.
Acknowledgements
This work was funded by the Austrian Science Fund (FWF):
P22931-B18 to NS.
References
Aerni, A., Traber, R., Hock, C., Roozendaal, B., Schelling, G., Papassotiropoulos, A.,
Nitsch, R.M., Schnyder, U., de Quervain, D.J., 2004. Low-dose cortisol for
symptoms of posttraumatic stress disorder. Am. J. Psychiatry 161, 1488e1490.
Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., Olesen, J., 2005. Cost of disorders of
the brain in Europe. Eur. J. Neurol. 12 (Suppl. 1), 1e27.
Armstrong, D.J., Meenagh, G.K., Bickle, I., Lee, A.S., Curran, E.S., Finch, M.B., 2007.
Vitamin D deﬁciency is associated with anxiety and depression in ﬁbromyalgia.
Clin. Rheumatol. 26, 551e554.
Baker, D.G., West, S.A., Nicholson, W.E., Ekhator, N.N., Kasckow, J.W., Hill, K.K.,
Bruce, A.B., Orth, D.N., Geracioti Jr., T.D., 1999. Serial CSF corticotropin-releasinghormone levels and adrenocortical activity in combat veterans with post-
traumatic stress disorder. Am. J. Psychiatry 156, 585e588.
Beck, C.H., Fibiger, H.C., 1995. Conditioned fear-induced changes in behavior and in
the expression of the immediate early gene c-fos: with and without diazepam
pretreatment. J. Neurosci. 15, 709e720.
Belzung, C., 2001. Rodent models of anxiety-like behaviors: are they predictive for
compounds acting via non-benzodiazepine mechanisms? Curr. Opin. Investig.
Drugs 2, 1108e1111.
Belzung, C., Griebel, G., 2001. Measuring normal and pathological anxiety-like
behaviour in mice: a review. Behav. Brain Res. 125, 141e149.
Bentz, D., Michael, T., de Quervain, D.J., Wilhelm, F.H., 2010. Enhancing exposure
therapy for anxiety disorders with glucocorticoids: from basic mechanisms of
emotional learning to clinical applications. J. Anxiety Disord. 24, 223e230.
Bodnoff, S.R., Suranyi-Cadotte, B., Aitken, D.H., Quirion, R., Meaney, M.J., 1988. The
effects of chronic antidepressant treatment in an animal model of anxiety.
Psychopharmacology (Berl.) 95, 298e302.
Bodnoff, S.R., Suranyi-Cadotte, B., Quirion, R., Meaney, M.J., 1989. A comparison of
the effects of diazepam versus several typical and atypical anti-depressant
drugs in an animal model of anxiety. Psychopharmacology (Berl.) 97, 277e279.
Bosch, O.J., Kromer, S.A., Neumann, I.D., 2006. Prenatal stress: opposite effects on
anxiety and hypothalamic expression of vasopressin and corticotropin-
releasing hormone in rats selectively bred for high and low anxiety. Eur. J.
Neurosci. 23, 541e551.
Bouwknecht, A., Olivier, B., Paylor, R.E., 2007. The stress-induced hyperthermia
paradigm as a physiological animal model for anxiety: a review of pharmaco-
logical and genetic studies in the mouse. Neurosci. Biobehav. Rev. 31, 41e59.
Bremner, J.D., Licinio, J., Darnell, A., Krystal, J.H., Owens, M.J., Southwick, S.M.,
Nemeroff, C.B., Charney, D.S., 1997. Elevated CSF corticotropin-releasing factor
concentrations in posttraumatic stress disorder. Am. J. Psychiatry 154, 624e629.
Broadhurst, P.L., 1961. Analysis of maternal effects in the inheritance of behavior.
Anim. Behav. 9, 129e141.
Busquet, P., Khoi Nguyen, N., Schmid, E., Tanimoto, N., Seeliger, M.W., Ben-Yosef, T.,
Mizuno, F., Akopian, A., Striessnig, J., Singewald, N., 2009. CaV1.3 L-type Ca2þ
channels modulate depression-like behaviour in mice independent of deaf
phenotype. Int. J. Neuropsychopharmacol., 1e15.
Charney, D.S., Drevets, W.C., 2008. Neurobiological basis of anxiety disorders. In:
Davis, K.L., Charney, D., Coyle, J.T., Nemeroff, C. (Eds.), Neuropsychopharmacology e
5th Generation of Progress. American College of Neuropsychopharmacology,
Nashville.
Coppen, A., Bolander-Gouaille, C., 2005. Treatment of depression: time to consider
folic acid and vitamin B12. J. Psychopharmacol. 19, 59e65.
Crawley, J.N., 1981. Neuropharmacologic speciﬁcity of a simple animal model for the
behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav.15, 695e699.
Crawley, J.N., 2000. What’s Wrong with My Mouse? Behavioral Phenotyping of
Transgenic and Knockout Mice. Wiley-Liss.
Cryan, J.F., Holmes, A., 2005. The ascent of mouse: advances in modelling human
depression and anxiety. Nat. Rev. Drug Discov. 4, 775e790.
de Medeiros, M.A., Carlos Reis, L., Eugenio Mello, L., 2005. Stress-induced c-Fos
expression is differentially modulated by dexamethasone, diazepam and
imipramine. Neuropsychopharmacology 30, 1246e1256.
DeFries, J.C., Hegmann, J.P., Halcomb, R.A., 1974. Response to 20 generations of
selection for open-ﬁeld activity in mice. Behav. Biol. 11, 481e495.
Dulawa, S.C., Hen, R., 2005. Recent advances in animal models of chronic antide-
pressant effects: the novelty-induced hypophagia test. Neurosci. Biobehav. Rev.
29, 771e783.
Dulawa, S.C., Holick, K.A., Gundersen, B., Hen, R., 2004. Effects of chronic ﬂuoxetine
in animal models of anxiety and depression. Neuropsychopharmacology 29,
1321e1330.
German-Fattal, M., Lecerf, F., Sabbagh, F., Maurois, P., Durlach, J., Bac, P., 2008.
Neuroprotective gene proﬁle in the brain of magnesium-deﬁcient mice.
Biomed. Pharmacother. 62, 264e272.
Gobshtis, N., Ben-Shabat, S., Fride, E., 2007. Antidepressant-induced undesirable
weight gain: prevention with rimonabant without interference with behavioral
effectiveness. Eur. J. Pharmacol. 554, 155e163.
Gordon, J.A., Hen, R., 2004. Genetic approaches to the study of anxiety. Annu. Rev.
Neurosci. 27, 193e222.
Griebel, G., Belzung, C., Perrault, G., Sanger, D.J., 2000. Differences in anxiety-related
behaviours and in sensitivity to diazepam in inbred and outbred strains of mice.
Psychopharmacology (Berl.) 148, 164e170.
Guilloux, J.P., David, D.J., Xia, L., Nguyen, H.T., Rainer, Q., Guiard, B.P., Reperant, C.,
Deltheil, T., Toth,M., Hen, R., Gardier, A.M., 2011. Characterization of 5-HT(1A/1B)/
mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology 61,
478e488.
Hackbarth, H., Kuppers, N., Bohnet,W., 2000. Euthanasia of rats with carbon dioxidee
animal welfare aspects. Lab. Anim. 34, 91e96.
Haddad, J.J., 2005. N-methyl-D-aspartate (NMDA) and the regulation of mitogen-
activated protein kinase (MAPK) signaling pathways: a revolving neurochem-
ical axis for therapeutic intervention? Prog. Neurobiol. 77, 252e282.
Hayashida, S., Oka, T., Mera, T., Tsuji, S., 2010. Repeated social defeat stress induces
chronic hyperthermia in rats. Physiol. Behav. 101, 124e131.
Held, K., Antonijevic, I.A., Kunzel, H., Uhr, M., Wetter, T.C., Golly, I.C., Steiger, A.,
Murck, H., 2002. Oral Mg(2þ) supplementation reverses age-related neuroen-
docrine and sleep EEG changes in humans. Pharmacopsychiatry 35, 135e143.
Holsboer, F., 2000. The corticosteroid receptor hypothesis of depression. Neuro-
psychopharmacology 23, 477e501.
S.B. Sartori et al. / Neuropharmacology 62 (2012) 304e312312Imaki, T., Wang, X.Q., Shibasaki, T., Harada, S., Chikada, N., Takahashi, C., Naruse, M.,
Demura, H., 1995. Chlordiazepoxide attenuates stress-induced activation of neurons,
corticotropin-releasing factor (CRF) gene transcription and CRF biosynthesis in the
paraventricular nucleus (PVN). Brain Res. Mol. Brain Res. 32, 261e270.
Jacka, F.N., Overland, S., Stewart, R., Tell, G.S., Bjelland, I., Mykletun, A., 2009. Asso-
ciation between magnesium intake and depression and anxiety in community-
dwelling adults: the Hordaland health study. Aust. N. Z. J. Psychiatry 43, 45e52.
Jingami, H., Mizuno, N., Takahashi, H., Shibahara, S., Furutani, Y., Imura, H., Numa, S.,
1985. Cloning and sequence analysis of cDNA for rat corticotropin-releasing
factor precursor. FEBS Lett. 191, 63e66.
Kantak, K.M., 1988. Magnesium deﬁciency alters aggressive behavior and cate-
cholamine function. Behav. Neurosci. 102, 304e311.
Keck, M.E., Sartori, S.B., Welt, T., Muller, M.B., Ohl, F., Holsboer, F., Landgraf, R.,
Singewald, N., 2005. Differences in serotonergic neurotransmission between
rats displaying high or low anxiety/depression-like behaviour: effects of
chronic paroxetine treatment. J. Neurochem. 92, 1170e1179.
Keegan, C.E., Herman, J.P., Karolyi, I.J., O’Shea, K.S., Camper, S.A., Seasholtz, A.F., 1994.
Differential expression of corticotropin-releasing hormone in developing
mouse embryos and adult brain. Endocrinology 134, 2547e2555.
Keeney, A.J., Hogg, S., Marsden, C.A., 2001. Alterations in core body temperature,
locomotor activity, and corticosterone following acute and repeated social
defeat of male NMRI mice. Physiol. Behav. 74, 177e184.
Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., 2005.
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the
national comorbidity survey replication. Arch. Gen. Psychiatry 62, 593e602.
Kroll, J.L., 2007. New directions in the conceptualization of psychotic disorders. Curr.
Opin. Psychiatry 20, 573e577.
Kromer, S.A., Kessler, M.S., Milfay, D., Birg, I.N., Bunck, M., Czibere, L., Panhuysen, M.,
Putz, B., Deussing, J.M., Holsboer, F., Landgraf, R., Turck, C.W., 2005. Identiﬁca-
tion of glyoxalase-I as a protein marker in a mouse model of extremes in trait
anxiety. J. Neurosci. 25, 4375e4384.
Laarakker, M.C., van Lith, H.A., Ohl, F., 2011. Behavioral characterization of A/J and
C57BL/6J mice using a multidimensional test: association between blood
plasma and brain magnesium-ion concentration with anxiety. Physiol. Behav.
102, 205e219.
Lecci, A., Borsini, F., Volterra, G., Meli, A., 1990. Pharmacological validation of a novel
animal model of anticipatory anxiety in mice. Psychopharmacology (Berl.) 101,
255e261.
Liebowitz, M.R., 1997. Panic disorder as a chronic illness. J. Clin. Psychiatry 58
(Suppl. 13), 5e8.
Liebsch, G., Linthorst, A.C., Neumann, I.D., Reul, J.M., Holsboer, F., Landgraf, R., 1998.
Behavioral, physiological, and neuroendocrine stress responses and differential
sensitivity to diazepam in two Wistar rat lines selectively bred for high- and
low-anxiety-related behavior. Neuropsychopharmacology 19, 381e396.
Lowry, C.A., Moore, F.L., 2006. Regulation of behavioral responses by corticotropin-
releasing factor. Gen. Comp. Endocrinol. 146, 19e27.
Merali, Z., Levac, C., Anisman, H., 2003. Validation of a simple, ethologically relevant
paradigm for assessing anxiety in mice. Biol. Psychiatry 54, 552e565.
Millan, M.J., 2003. The neurobiology and control of anxious states. Prog. Neurobiol.
70, 83e244.
Muigg, P., Scheiber, S., Salchner, P., Bunck, M., Landgraf, R., Singewald, N., 2009.
Differential stress-induced neuronal activation patterns in mouse lines selec-
tively bred for high, normal or low anxiety. PLoS One 4, e5346.
Murck, H., 2002. Magnesium and affective disorders. Nutr. Neurosci. 5, 375e389.
Murck, H., Steiger, A., 1998. Mg2þ reduces ACTH secretion and enhances spindle
power without changing delta power during sleep in men e possible thera-
peutic implications. Psychopharmacology (Berl.) 137, 247e252.
Muroyama, A., Inaka, M., Matsushima, H., Sugino, H., Marunaka, Y., Mitsumoto, Y.,
2009. Enhanced susceptibility to MPTP neurotoxicity in magnesium-deﬁcient
C57BL/6N mice. Neurosci. Res. 63, 72e75.
Nguyen, N.K., Sartori, S.B., Herzog, H., Tasan, R., Sperk, G., Singewald, N., 2009. Effect
of neuropeptide Y Y2 receptor deletion on emotional stress-induced neuronal
activation in mice. Synapse 63, 236e246.
O’Mahony, C.M., Sweeney, F.F., Daly, E., Dinan, T.G., Cryan, J.F., 2010. Restraint stress-
induced brain activation patterns in two strains of mice differing in their
anxiety behaviour. Behav. Brain Res. 213, 148e154.Paxinos, K.B.L., Franklin, G., 2001. The Mouse Brain in Stereotaxic Coordinates,
second ed. Academic Press, London.
Plag, J., Siegmund, A., Strohle, A., 2009. Pharmakotherapie bei Angsterkrankungen.
Z. Psychiatr. Psychol. Psychother. 57, 185e194.
Poleszak, E., Szewczyk, B., Kedzierska, E., Wlaz, P., Pilc, A., Nowak, G., 2004. Anti-
depressant- and anxiolytic-like activity of magnesium in mice. Pharmacol.
Biochem. Behav. 78, 7e12.
Popkin, B.M., 2006. Global nutrition dynamics: the world is shifting rapidly
toward a diet linked with noncommunicable diseases. Am. J. Clin. Nutr. 84,
289e298.
Salome, N., Salchner, P., Viltart, O., Sequeira, H., Wigger, A., Landgraf, R.,
Singewald, N., 2004. Neurobiological correlates of high (HAB) versus low
anxiety-related behavior (LAB): differential Fos expression in HAB and LAB rats.
Biol. Psychiatry 55, 715e723.
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N.,
Lee, J., Duman, R., Arancio, O., Belzung, C., Hen, R., 2003. Requirement of
hippocampal neurogenesis for the behavioral effects of antidepressants. Science
301, 805e809.
Sartori, S.B., Burnet, P.W., Sharp, T., Singewald, N., 2004. Evaluation of the effect of
chronic antidepressant treatment on neurokinin-1 receptor expression in the
rat brain. Neuropharmacology 46, 1177e1183.
Sartori, S.B., Landgraf, R., Singewald, N., 2011. The clinical implications of mouse
models of enhanced anxiety. Future Neurol 6, 531e571.
Seelig, M.S., 1994. Consequences of magnesium deﬁciency on the enhancement of
stress reactions; preventive and therapeutic implications (a review). J. Am. Coll.
Nutr. 13, 429e446.
Singewald, N., Salchner, P., Sharp, T., 2003. Induction of c-Fos expression in speciﬁc
areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol. Psychiatry
53, 275e283.
Singewald, N., Sinner, C., Hetzenauer, A., Sartori, S.B., Murck, H., 2004. Magnesium-
deﬁcient diet alters depression- and anxiety-related behavior in mice e inﬂu-
ence of desipramine and Hypericum perforatum extract. Neuropharmacology 47,
1189e1197.
Soravia, L.M., Heinrichs, M., Aerni, A., Maroni, C., Schelling, G., Ehlert, U.,
Roozendaal, B., de Quervain, D.J., 2006. Glucocorticoids reduce phobic fear in
humans. Proc. Natl. Acad. Sci. U.S.A. 103, 5585e5590.
Thys-Jacobs, S., 2000. Micronutrients and the premenstrual syndrome: the case for
calcium. J. Am. Coll. Nutr. 19, 220e227.
Tschenett, A., Singewald, N., Carli, M., Balducci, C., Salchner, P., Vezzani, A.,
Herzog, H., Sperk, G., 2003. Reduced anxiety and improved stress coping ability
in mice lacking NPY-Y2 receptors. Eur. J. Neurosci. 18, 143e148.
Veenema, A.H., Meijer, O.C., de Kloet, E.R., Koolhaas, J.M., Bohus, B.G., 2003.
Differences in basal and stress-induced HPA regulation of wild house mice
selected for high and low aggression. Horm. Behav. 43, 197e204.
Vinkers, C.H., van Bogaert, M.J., Klanker, M., Korte, S.M., Oosting, R., Hanania, T.,
Hopkins, S.C., Olivier, B., Groenink, L., 2008. Translational aspects of pharma-
cological research into anxiety disorders: the stress-induced hyperthermia
(SIH) paradigm. Eur. J. Pharmacol. 585, 407e425.
Whittle, N., Li, L., Chen, W.Q., Yang, J.W., Sartori, S.B., Lubec, G., Singewald, N., 2011.
Changes in brain protein expression are linked to magnesium restriction-
induced depression-like behavior. Amino Acids 40, 1231e1248.
Whittle, N., Lubec, G., Singewald, N., 2009. Zinc deﬁciency induces enhanced
depression-like behaviour and altered limbic activation reversed by antide-
pressant treatment in mice. Amino Acids 36, 147e158.
WHO, 2004. Global burden of disease report.
Yalcin, I., Aksu, F., Belzung, C., 2005. Effects of desipramine and tramadol in
a chronic mild stress model in mice are altered by yohimbine but not by pin-
dolol. Eur. J. Pharmacol. 514, 165e174.
Young, E.A., Abelson, J.L., Liberzon, I., 2008. Stress hormones and anxiety disorders.
In: Blanchard, R.J., Blanchard, D.C., Griebel, G., Nutt, D. (Eds.), Handbook of
Anxiety and Fear. Academic Press, Oxford, pp. 455e473.
Zamorski, M.A., Albucher, R.C., 2002. What to do when SSRIs fail: eight strategies
for optimizing treatment of panic disorder. Am. Fam. Physician 66,
1477e1484.
Zender, R., Olshansky, E., 2009. Women’s mental health: depression and anxiety.
Nurs. Clin. North Am. 44, 355e364.
